Tetrazine-mediated bioorthogonal prodrug–prodrug activation
Chemical Science2018Vol. 9(36), pp. 7198–7203
Citations Over TimeTop 10% of 2018 papers
Abstract
The selective and biocompatible activation of prodrugs within complex biological systems remains a key challenge in medical chemistry and chemical biology. Herein we report, for the first time, a dual prodrug activation strategy that fully satisfies the principle of bioorthogonality by the symbiotic formation of two active drugs. This dual and traceless prodrug activation strategy takes advantage of the INVDA chemistry of tetrazines (here a prodrug), generating a pyridazine-based miR21 inhibitor and the anti-cancer drug camptothecin and offers a new concept in prodrug activation.
Related Papers
- → Light-activated tetrazines enable precision live-cell bioorthogonal chemistry(2022)130 cited
- → Overview of Syntheses and Molecular-Design Strategies for Tetrazine-Based Fluorogenic Probes(2021)49 cited
- → A tetrazine-fused aggregation induced emission luminogen for bioorthogonal fluorogenic bioprobe(2021)28 cited
- → Tetrazine‐Isonitrile Bioorthogonal Fluorogenic Reactions Enable Multiplex Labeling and Wash‐Free Bioimaging of Live Cells(2024)3 cited
- → Control of tetrazine bioorthogonal reactivity by naphthotube and phenyltetrazine host-guest pairs(2023)3 cited